Novel Sulfated Oligosaccharide DP9 from Marine Algae, Gracilaria lemaneiformis: A Potent Galectin-3 Inhibitor for Pancreatic Cancer Therapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A novel marine oligosaccharide, DP9, effectively inhibits galectin-3 (Gal-3), a marker for pancreatic cancer. This compound shows potential as a therapeutic agent by selectively targeting pancreatic cancer cells and inhibiting their growth and spread.
Area Of Science
- Marine Biotechnology
- Carbohydrate Chemistry
- Cancer Therapeutics
Background
- Galectin-3 (Gal-3) is a key marker and therapeutic target in pancreatic cancer.
- Marine algae are a source of novel bioactive compounds with therapeutic potential.
Purpose Of The Study
- To characterize a novel sulfated oligosaccharide (DP9) from *Gracilaria lemaneiformis*.
- To evaluate DP9's galectin-3 inhibitory activity and anti-pancreatic cancer mechanisms.
Main Methods
- Controlled acid hydrolysis of marine algae to obtain oligosaccharides.
- Hemagglutination assays for galectin-3 inhibition screening.
- Structural analysis (NMR, MS) and molecular docking.
- In vitro studies on pancreatic cancer cell lines (proliferation, cell cycle, apoptosis, migration, invasion).
Main Results
- DP9, an agarose-derived oligosaccharide, demonstrated potent galectin-3 inhibition.
- Structural analysis revealed a unique backbone with methylation and sulfation enhancing binding.
- DP9 selectively inhibited pancreatic cancer cell proliferation, induced cell cycle arrest and apoptosis, and suppressed migration/invasion.
- DP9 attenuated the Gal-3/EGFR/AKT/FOXO3 signaling pathway with minimal toxicity to normal cells.
Conclusions
- Agarose-derived oligosaccharides, specifically DP9, are effective galectin-3 inhibitors.
- DP9 exhibits significant potential as a marine oligosaccharide-based therapeutic agent for pancreatic cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...